受体链也被多种细胞因子使用。IL-12通过IL-12Rβ1和IL-12Rβ2发出信号,而IL-23通过IL-12Rβ1和IL-23R发出信号。相比之下,IL-27通过gp130和IL-27R(WSX-1)发出信号,而IL-35通过gp130和IL-12Rβ2发出信号。IL-35的不同在于,它还可以通过额外两种受体链组合发出信号: gp130-gp130和IL-12Rβ2-lL-12Rβ...
细胞因子信号传导的一个关键特征是利用共享信号受体(shared signaling receptors)作为多种细胞因子的共同信号转导亚基,这也是调节生理学多效性的普遍机制之一,细胞因子通过细胞表面受体的多聚化和JAK-STAT信号通路来调控【1】。白介素-12(IL-12)是第一个被鉴定的异二聚体细胞因子,然而,毒性一直是IL-12临床应用的...
STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immu- nity in cutaneous leishmaniasis. Eur. J. Immunol. 29:2524- 2529.Stamm LM, Satoskar AA, Ghosh SK, et al. STAT4 mediated IL- l2 signaling pathway is critical for the development of protecti...
and costimulatory molecules on macrophages. It also enhances B cell survival, proliferation, and antibody production. This cytokine can block NF-kappa B activity, and is involved in the regulation of the JAK-STAT signaling pathway. Knockout studies in mice suggested the function of this cytokine ...
IL-12 family receptors exert their funcitons by binding to their heterodimeric IL-12 family cytokines which can often act synergistically to promote Th1 responses and interferon-γ (IFN-γ) production by T cells. IL-12 Family Signaling Pathway ...
7D, E), supporting the IL-12 regulation of hepatocyte IRS2-FoxO1 signaling pathway. Hepatocyte transcription factor FoxO1 was recently shown to be a potent negative regulator of FGF21 secretion from the liver48,79,80. In that regard, we found a 20-fold increase in hepatocyte FGF21 mRNA ...
[18]Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, Vande Casteele N. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology. 2023 Jul;20(7):433-46.
CAR T cell-mediated IFNγ production facilitated by IL-12 signaling is required for tumor cell killing, which is recapitulated by engineering an optimized membrane-bound IL-12 (mbIL12) molecule in CAR T cells. These T cells show improved antigen-dependent T cell proliferation and recursive tumor...
IL-12 x IL-23 作用机制 IL-12抑制剂[+1] 在研机构 Biocon Ltd.[+3] 原研机构 Biocon Ltd. 在研适应症 银屑病关节炎[+7] 非在研适应症- 最高研发阶段批准上市 首次获批国家/地区 美国 首次获批日期2024-11-29 Ustekinumab Biosimilar (Qyuns Therapeutics) ...
signaling pathway cellular response to virus positive regulation of dendritic cell chemotaxis positive regulation of defense response to virus by host natural killer cell activation involved in immune response positive regulation of T-helper 1 type immune response negative regulation of inflammatory response...